BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou L, Zhang Y, Wang Y, Zhang M, Sun W, Dai T, Wang A, Wu X, Zhang S, Wang S, Zhou F. A Dual Role of Type I Interferons in Antitumor Immunity. Adv Biosyst 2020;4:e1900237. [PMID: 33245214 DOI: 10.1002/adbi.201900237] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Zoellner N, Coesfeld N, De Vos FH, Denter J, Xu HC, Zimmer E, Knebel B, Al-hasani H, Mossner S, Lang PA, Floss DM, Scheller J. Synthetic mimetics assigned a major role to IFNAR2 in type I interferon signaling. Front Microbiol 2022;13:947169. [DOI: 10.3389/fmicb.2022.947169] [Reference Citation Analysis]
2 Yu R, Zhu B, Chen D. Type I interferon-mediated tumor immunity and its role in immunotherapy. Cell Mol Life Sci 2022;79:191. [PMID: 35292881 DOI: 10.1007/s00018-022-04219-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
3 Tang T, Huang X, Zhang G, Lu M, Hong Z, Wang M, Huang J, Zhi X, Liang T. Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis. J Immunother Cancer 2022;10:e004129. [PMID: 35288467 DOI: 10.1136/jitc-2021-004129] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Grard M, Chatelain C, Delaunay T, Pons-Tostivint E, Bennouna J, Fonteneau JF. Homozygous Co-Deletion of Type I Interferons and CDKN2A Genes in Thoracic Cancers: Potential Consequences for Therapy. Front Oncol 2021;11:695770. [PMID: 34249754 DOI: 10.3389/fonc.2021.695770] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Amouzegar A, Chelvanambi M, Filderman JN, Storkus WJ, Luke JJ. STING Agonists as Cancer Therapeutics. Cancers (Basel) 2021;13:2695. [PMID: 34070756 DOI: 10.3390/cancers13112695] [Cited by in Crossref: 2] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
6 Geoffroy K, Bourgeois-Daigneault MC. The pros and cons of interferons for oncolytic virotherapy. Cytokine Growth Factor Rev 2020;56:49-58. [PMID: 32694051 DOI: 10.1016/j.cytogfr.2020.07.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]